Whalesbook
Apollo Hospitals ke Demerger Plans se Badhi Umeed
Prabhudas Lilladher ne Apollo Hospitals Enterprise par apna 'BUY' recommendation pakka rakha hai aur target price ko ₹9,350 kar diya hai. Brokerage ka confidence company ke zabardast financial performance se aa raha hai. Inhone consolidate EBITDA ₹10.1 billion report kiya hai, jo estimates se 5% zyada tha aur pichhle saal se 31% upar hai. Special costs ko adjust karne ke baad bhi, adjusted EBITDA ₹11.1 billion raha, jo 19% ka jump hai.
Brokerage ki positive outlook ke peeche HealthCo stake ko Advent ko bechna aur Keimed ke saath merger jaise strategic divestments hain. Yeh sab milkar ek comprehensive pharmacy aur digital health ecosystem bana rahe hain. Iske alawa, Apollo Hospitals apne '24*7' pharmacy business aur telehealth services ko ek alag, publicly traded company mein demerge karne ka plan bana rahi hai. Is separation se shareholders ke liye value unlock hone ki ummeed hai, kyunki yeh focused businesses apne growth par dhyan de payenge. Report hai ki digital segment agle kuch quarters mein profit mein aa jayega.
Growth Projections aur Market Mein Position
Aagey dekhte hue, Prabhudas Lilladher ko Apollo Hospitals Enterprise ke liye FY26 se FY28 ke beech EBITDA mein 25% ka strong CAGR (Compound Annual Growth Rate) dikh raha hai. FY27 aur FY28 ke liye EBITDA estimates mein 2% ka halka increase bhi kiya gaya hai. Valuation ke liye, hospital aur offline pharmacy operations ke liye 25x EV/EBITDA multiple aur AHLL business ke liye 20x EV/EBITDA multiple use kiya gaya hai, jo alag alag divisions ke growth potential ko dikhata hai.
Bade healthcare market mein, Fortis Healthcare aur Max Healthcare jaise competitors bhi capacity expansion aur digital integration par kaam kar rahe hain. Lekin Apollo ka consumer-focused digital aur pharmacy businesses ko alag karne ka decision unhe specific market segments mein better perform karne mein madad kar sakta hai. Analysts generally un companies ko favor kar rahe hain jo margin improvement aur efficient capital use ka clear strategy dikha rahi hain, aur Apollo ka move specialized growth par focus kar raha hai.
Potential Risks Aur Challenges
Sab kuch achha lag raha hai, par investors ko kuch risks ka bhi dhyan rakhna chahiye. Demerger ka success execution par depend karega aur naye businesses ko apne growth targets achieve karne honge, bina core hospital business ko affect kiye. Market volatility, regulatory changes ya government healthcare policies mein shifts bhi profitability ko affect kar sakte hain. HealthCo aur Keimed ka integration bhi execution risks ke saath aata hai. Koi bhi delay ya unexpected issue anticipated benefits ko kam kar sakta hai.
Investors ko yeh bhi dekhna hoga ki dusre integrated healthcare providers kaise respond karte hain aur digital health landscape ko monitor karna hoga, jismein continuous innovation aur investment chahiye.
Future Strategy Par Focus
Yeh strategic realignment, khaas kar pharmacy aur digital health operations ka demerger, Apollo Hospitals ka focus badhane aur hidden value unlock karne ka commitment dikhata hai. FY26 se FY28 ke beech company ke performance mein tez EBITDA growth dekhne ko mil sakti hai, jo hospital segment aur digital health platform se fuel hogi. Market closely observe karega ki kaise yeh demerged businesses India ke badhte healthcare aur pharmaceutical sectors mein independent growth drivers bante hain.